Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: A single centre experience

European Journal of Haematology

Volumn 86, Issue 4, 2011, Pages 299-304

  Jantunen, Esa ^a,b   Kuittinen, Taru ^a   Mahlamäki, Eija ^c   Pyörälä, Marja ^a   Mäntymaa, Pentti ^c   Nousiainen, Tapio ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c OK Kuopio   (Finland)

Author keywords

Lymphoma; Myeloma; Plerixafor; Poor mobilization; Pre emptive use; Stem cells

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; PLERIXAFOR; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HOSPITAL ADMISSION; HUMAN; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PATIENT SAFETY; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; STEM CELL MOBILIZATION; TREATMENT FAILURE; TUMOR ENGRAFTMENT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FILGRASTIM; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECEPTORS, CXCR4; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79952768349     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01573.x     Document Type: Article

References (19)

1. Jantunen E, Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010;85:463-71.
2. Pusic I, Jiang SY, Landua S, et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008;14:1045-56.
3. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells - definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010;16:490-9.
4. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009;43:181-95.
5. Steinberg M, Silva M. Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Clin Ther 2010;32:821-43.
6. Lemoli RM, d'Addio A. Hematopoietic stem cell mobilization. Haematologica 2008;83:321-4.
7. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005;106:1867-74.
8. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008;41:331-8.
9. DiPersio JF, Stadtmayer EA, Nademanee A, et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009;113:5720-6.
10. DiPersio JF, Micallef I, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4767-73.
11. Jantunen E, Penttilä K, Pyörälä M, Mahlamäki E, Kuittinen T, Nousiainen T. Addition of plerixafor to a chemotherapy and G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplant 2010, April 19 e-pub.
12. d'Addio A, Curti A, Worel N, et al. The addition of plerixafor is safe and allow adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2010, May 31 e-pub.
13. Josefsen D, Rechnitzer C, Parto K, Kvalheim G. The use of plerixafor for blood stem cell mobilization reduces the frequency of mobilization failure in patients planned to undergo autologous transplantation. Eur Hematol 2010;4:24-9.
14. Segel E, Sorensen B, d'Amore F, Hokland P. Successful peripheral blood stem cell harvest in mobilization refractory lymphoma patients. Bone Marrow Transplant 2010;45(Suppl. 2):S258. (Abstract).
15. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010;45:39-47.
16. Hubel K, Fresen MM, Salwender H, et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2010, Oct 25 e-pub.
17. Jantunen E, Kuittinen T. Blood stem cell mobilization and collection is patients with lymphoproliferative diseases: practical issues. Eur J Haematol 2008;80:287-95.
18. Fruehauf S, Tricot G. Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplant outcomes. Biol Blood Marrow Transplant 2010;16:1629-1648.
19. Jantunen E, Fruehauf S. Importance of blood graft characteristics in autologous stem cell transplantation: implications for optimizing mobilization regimens. Bone Marrow Transplant 2011, Jan 10 e-pub.